Nordicus Partners Corporation Appoints Three New Members to Its Board of Directors
Nordicus Partners Corporation (OTCQB: NORD), a business accelerator focused on Nordic and U.S. life sciences companies, announced significant changes to its Board of Directors. The company expanded its board from three to five members, with Henrik Keller resigning and three new directors joining: Torben Jensen (major shareholder), Kim T. M眉cke (accounting expert and future Audit Committee chairman), and Andrew J. Ritter (experienced pharma CEO).
The new appointments align with Nordicus's strategy to acquire majority stakes in Nordic and U.S.-based life sciences companies, bringing expertise in funding, accounting, and strategic relationships.
Nordicus Partners Corporation (OTCQB: NORD), un acceleratore d'impresa focalizzato sulle aziende nordiche e statunitensi nel settore delle scienze della vita, ha annunciato importanti cambiamenti nel suo Consiglio di Amministrazione. La societ脿 ha ampliato il consiglio da tre a cinque membri, con le dimissioni di Henrik Keller e l'ingresso di tre nuovi direttori: Torben Jensen (azionista di maggioranza), Kim T. M眉cke (esperto contabile e futuro presidente del Comitato di Revisione) e Andrew J. Ritter (CEO esperto nel settore farmaceutico).
Le nuove nomine sono in linea con la strategia di Nordicus di acquisire partecipazioni di maggioranza in aziende di scienze della vita con sede nei Paesi nordici e negli Stati Uniti, apportando competenze in finanziamenti, contabilit脿 e relazioni strategiche.
Nordicus Partners Corporation (OTCQB: NORD), un acelerador de negocios enfocado en empresas de ciencias de la vida de los pa铆ses n贸rdicos y Estados Unidos, anunci贸 cambios significativos en su Junta Directiva. La compa帽铆a ampli贸 su junta de tres a cinco miembros, con la renuncia de Henrik Keller y la incorporaci贸n de tres nuevos directores: Torben Jensen (accionista mayoritario), Kim T. M眉cke (experto en contabilidad y futuro presidente del Comit茅 de Auditor铆a) y Andrew J. Ritter (CEO experimentado en la industria farmac茅utica).
Las nuevas designaciones est谩n alineadas con la estrategia de Nordicus de adquirir participaciones mayoritarias en empresas de ciencias de la vida con sede en los pa铆ses n贸rdicos y Estados Unidos, aportando experiencia en financiamiento, contabilidad y relaciones estrat茅gicas.
Nordicus Partners Corporation (OTCQB: NORD)電� 攵侅湢霟� 氚� 氙戈淡 靸濍獏瓿柬暀 旮办梾鞐� 欷戩爯鞚� 霊� 牍勳雼堨姢 鞎§厐霟爤鞚错劙搿滌劀 鞚挫偓須岇潣 欷戨寑頃� 氤�頇旊ゼ 氚滍憸頄堨姷雼堧嫟. 須岇偓電� 鞚挫偓須岆ゼ 3氇呾棎靹� 5氇呾溂搿� 頇曤寑頄堨溂氅�, 項Ν 旒堧煬臧� 靷瀯頃橁碃 靹� 氇呾潣 鞁犼窚 鞚挫偓臧� 頃╇頄堨姷雼堧嫟: 韱犽ゴ氩� 鞓岇劶 (欤检殧 欤检＜), 韨� T. 氘堨紑 (須岅硠 鞝勲臧�鞚挫瀽 頄ロ泟 臧愳偓鞙勳洂須� 鞚橃灔), 攴鸽Μ瓿� 鞎る摐毳� J. 毽劙 (瓴巾棙 毵庫潃 鞝滌暯 CEO)鞛呺媹雼�.
鞚措矆 鞁犼窚 鞛勲獏鞚� 攵侅湢霟� 氚� 氙戈淡鞐� 旮半皹鞚� 霊� 靸濍獏瓿柬暀 旮办梾鞚� 瓿茧皹 歆�攵� 鞚胳垬毳� 氇╉憸搿� 頃橂姅 Nordicus鞚� 鞝勲灥瓿� 攵�頃╉晿氅�, 鞛愱笀 臁半嫭, 須岅硠 氚� 鞝勲灥鞝� 甏�瓿勳棎 雽�頃� 鞝勲靹膘潉 鞝滉车頃╇媹雼�.
Nordicus Partners Corporation (OTCQB : NORD), un acc茅l茅rateur d'entreprises ax茅 sur les soci茅t茅s des sciences de la vie nordiques et am茅ricaines, a annonc茅 des changements importants au sein de son conseil d'administration. La soci茅t茅 a 茅largi son conseil de trois 脿 cinq membres, avec la d茅mission de Henrik Keller et l'arriv茅e de trois nouveaux administrateurs : Torben Jensen (actionnaire majoritaire), Kim T. M眉cke (expert en comptabilit茅 et futur pr茅sident du comit茅 d'audit) et Andrew J. Ritter (PDG exp茅riment茅 dans le secteur pharmaceutique).
Ces nouvelles nominations s'alignent sur la strat茅gie de Nordicus visant 脿 acqu茅rir des participations majoritaires dans des entreprises des sciences de la vie bas茅es en Scandinavie et aux 脡tats-Unis, apportant une expertise en financement, comptabilit茅 et relations strat茅giques.
Nordicus Partners Corporation (OTCQB: NORD), ein Business Accelerator mit Fokus auf nordische und US-amerikanische Life-Sciences-Unternehmen, gab bedeutende Ver盲nderungen in seinem Vorstand bekannt. Das Unternehmen erweiterte seinen Vorstand von drei auf f眉nf Mitglieder, wobei Henrik Keller zur眉cktrat und drei neue Direktoren hinzukamen: Torben Jensen (惭别丑谤丑别颈迟蝉补办迟颈辞苍盲谤), Kim T. M眉cke (Bilanzexperte und zuk眉nftiger Vorsitzender des Pr眉fungsausschusses) sowie Andrew J. Ritter (erfahrener Pharma-CEO).
Die neuen Ernennungen stehen im Einklang mit der Strategie von Nordicus, Mehrheitsbeteiligungen an nordischen und US-amerikanischen Life-Sciences-Unternehmen zu erwerben und bringen Expertise in Finanzierung, Buchhaltung und strategischen Beziehungen mit.
- Board expansion from 3 to 5 members indicates corporate governance enhancement
- Addition of experienced directors with complementary expertise in funding, accounting, and pharma industry
- New director Torben Jensen is already a major shareholder, showing alignment with investor interests
- Addition of experienced public company CEO strengthens strategic acquisition capabilities
- Resignation of board member Henrik Keller creates potential continuity gap
- Significant board restructuring may temporarily impact decision-making processes
Beverly Hills, California, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Nordicus Partners Corporation (OTCQB: NORD) (鈥淣ordicus鈥� or the 鈥淐ompany鈥�), a business accelerator and holding company specializing in providing Nordic and U.S. life sciences companies with optimal conditions to establish themselves on the U.S. market, announced today that Henrik Keller resigned from the Board of Directors (the 鈥淏oard鈥�) of Nordicus to pursue other interests; that the Board has been increased from three to five members; and that Torben Jensen, Kim T. M眉cke and Andrew J. Ritter have been appointed to fill the vacancies on the Board.
鈥淲e thank Henrik Keller for his service to our company,鈥� said Henrik Rouf, CEO of Nordicus, 鈥渁nd welcome our three new board members. Mr. Jensen is already a major shareholder and will continue to provide valuable assistance in funding Nordicus and its subsidiaries. Mr. M眉cke brings us many years of experience in the accounting industry and will play a key role as chairman of our Board鈥檚 Audit Committee. Mr. Ritter is an experienced CEO of public companies in the pharma space and will be invaluable in assisting us in both corporate finance and establishing strategic relationships with potential acquirers of our products. All three will be invaluable to Nordicus as we pursue our mission to acquire majority stakes in Nordic- as well as U.S.-based life sciences companies.鈥�
About Torben Jensen
Torben Jensen (60) has more than 35 years of experience in finance and has during the years developed and funded projects and companies in real estate, energy, venture, life science and medico. He has previously been CEO and Chairman of the Board of two listed companies on Nasdaq. From 2019 to 2024 he was a Senior Partner in GK Partners ApS, a corporate finance house and a major shareholder in Nordicus, where he was the head of funding for projects. Furthermore, he has served as the Chief Executive Officer of AC Nordic since December 2024, also a major shareholder in Nordicus.
About Kim T. M眉cke
Kim T. M眉cke is a Danish state authorized public accountant (authorization deposited in 2025). He was partner with Deloitte (Denmark) from 2002 to 2022 where he, among others, served as signing partner for various listed companies including companies that underwent IPO processes. In the years 2023-2024, Mr. M眉cke was Head of Corporate Clients for BDO (Denmark). From January 1, 2025, Mr. M眉cke has started as independent advisor, specialized in financial reporting, risk management and corporate governance. Mr. M眉cke has a master鈥檚 degree in Auditing and Accounting from the Copenhagen Business School.
About Andrew J. Ritter
Andrew J. Ritter has served as the Chief Executive Officer and a director of Cairns Health, an innovator in AI-powered remote care solutions supporting home and senior care, since September 2023. Previously, Mr. Ritter was the Chief Executive Officer of Docbot, an AI-driven MedTech company, from January 2021 to December 2022. He also founded and served as Chief Executive Officer of Ritter Pharmaceuticals, a biotechnology company focusing on gastrointestinal diseases, from March 2004 to May 2020. In addition, he served as a founding director of Myosin Therapeutics, a biotech spin-out from Scripps Research, from October 2021 to January 2025. Mr. Ritter earned a B.A. in political science at the University of Southern California and a Master of Business Administration at the Wharton School, University of Pennsylvania.
About Nordicus Partners Corporation
Nordicus Partners Corporation is the only U.S. publicly traded business accelerator and holding company for Nordic life sciences companies. Leveraging decades of combined management experience in domestic and global corporate sectors, Nordicus excels in corporate finance activities including business and market development, growth strategies, talent acquisition, partnership building, capital raising, and facilitating company acquisitions and sales. In 2024, Nordicus acquired
Forward-Looking Statements
This press release may contain forward-looking statements that involve substantial risks and uncertainties. You can identify these statements by the use of forward-looking terminology such as 鈥渕ay,鈥� 鈥渨ill,鈥� 鈥渟hould,鈥� 鈥渆xpect,鈥� 鈥渁nticipate,鈥� 鈥減roject,鈥� 鈥渆stimate,鈥� 鈥渋ntend,鈥� 鈥渃ontinue鈥� or 鈥渂elieve鈥� or the negatives thereof or other variations thereon or comparable terminology. You should read statements that contain these words carefully because they discuss our plans, strategies, prospects and expectations concerning our business, operating results, financial condition and other similar matters. We believe that it is important to communicate our future expectations to our investors. There may be events in the future, however, that we are not able to predict accurately or control. Any forward-looking statement made by us in this press release speaks only as of the date on which we make it. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
For further information contact
Mr. Henrik Rouf
Chief Executive Officer
Phone +1 310 666.0750
Email
FAQ
Who are the new board members appointed to Nordicus Partners (OTCQB: NORD)?
Why did Nordicus Partners expand its board of directors in August 2025?
What is Nordicus Partners' (NORD) business focus?
Who replaced Henrik Keller on Nordicus Partners' board?
What experience do the new Nordicus (NORD) board members bring?
